The checkpoint debate is about to get real

<!DOCTYPE html> <html lang="en"> <head> <title>The checkpoint debate is about to get real - Endpoints Webinars</title> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta http-equiv="content-type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width, user-scalable=no"> <link rel="apple-touch-icon" sizes="180x180" href="/assets/images/favicon/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/assets/images/favicon/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/assets/images/favicon/favicon-16x16.png"> <link rel="manifest" href="/assets/images/favicon/site.webmanifest"> <link rel="mask-icon" href="/assets/images/favicon/safari-pinned-tab.svg" color="#5bbad5"> <link rel="shortcut icon" href="/assets/images/favicon/favicon.ico"> <meta name="msapplication-TileColor" content="#da532c"> <meta name="msapplication-config" content="/assets/images/favicon/browserconfig.xml"> <meta name="theme-color" content="#ffffff"> <meta property="og:description" content="Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But" /> <meta property="og:title" content="The checkpoint debate is about to get real - Endpoints Webinars" /> <meta property="og:url" content="https://webinars.endpts.com/the-checkpoint-debate-is-about-to-get-real/" /> <meta property="og:site_name" content="Endpoints Webinars" /> <meta property="og:type" content="article" /> <meta property="article:section" content="Business & Health" /> <meta name="twitter:site" content="@endpts"> <link rel="canonical" href="https://webinars.endpts.com/the-checkpoint-debate-is-about-to-get-real/" /> <meta property="og:image" content="https://webinars.endpts.com/assets/images/the-checkpoint-debate-is-about-to-get-real/social_preview.jpg" /> <meta property="twitter:image" content="https://webinars.endpts.com/assets/images/the-checkpoint-debate-is-about-to-get-real/social_preview.jpg" /> <meta name="twitter:card" content="summary_large_image"><link href="https://webinars.endpts.com/assets/css/bootstrap.min.css" rel="stylesheet" type="text/css"> <link href="https://webinars.endpts.com/assets/css/style.css?v=1.0.17" rel="stylesheet" type="text/css"> <link href="https://webinars.endpts.com/assets/css/the-checkpoint-debate-is-about-to-get-real.css?v=1.0.17" rel="stylesheet" type="text/css"> <script async src="https://www.googletagmanager.com/gtag/js?id=G-ZS375P62LY"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ZS375P62LY'); gtag('config', 'AW-370093343'); </script> </head> <body id="page-the-checkpoint-debate-is-about-to-get-real"> <header class="header_area"> <div class="main_menu"> <nav class="navbar navbar-expand-lg navbar-light"> <div class="container navi-border"> <a href="/" title="Endpoints Webinars"> <div class="navbar-brand logo_h"> <svg version="1.1" width="280px" class="d-inline-block align-top ew-logo" alt="Endpoints Webinars" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewbox="0 0 280 46" style="enable-background:new 0 0 280 46;" xml:space="preserve"> <path class="ew-logo-primary" d="M84.3,0.2l-7.7,24.1h-0.5l-8-24.1h-7.8l-7.3,24.1h-0.5L44.3,0.2h-4h-8.8H0V46h39l-3.9-10.2h-24v-8.1h20.6 L28.1,18h-17v-7.6h24.3L48.7,46h7.7l8-25.6h0.4L72.2,46h7.7L97.1,0.2H84.3z"></path> <path class="ew-logo-secondary" d="M122.2,33.3l-4.5,12.5h-1l-7-17.7l2.5-0.5l4.9,12.8h0.2l4.5-12.8h0.6l4.7,12.8h0.2l4.8-12.8l2.5,0.5l-7,17.7h-1 L122.2,33.3C122.4,33.3,122.2,33.3,122.2,33.3z M151.2,30.1H142v5.3h8.1v2.3H142v5.7h9.5v2.3h-12.1V27.8h11.7L151.2,30.1L151.2,30.1 z M166.8,36.5c2.2,0.4,3.7,2.1,3.7,4.2c0,3.1-2.4,4.9-6.3,4.9h-6.4V27.8h5.9c4.2,0,5.8,2.4,5.8,4.7c0,1.6-0.8,3.1-2.6,3.8V36.5 L166.8,36.5z M163.7,30.1h-3.5v5.3h3.6c1.9,0,2.9-0.9,2.9-2.7C166.7,30.7,165.3,30.1,163.7,30.1z M160.2,37.7v5.7h4.2 c1.9,0,3.4-0.9,3.4-2.8s-1.6-2.9-3.6-2.9L160.2,37.7L160.2,37.7z M179.1,45.6h-2.5V27.8h2.5V45.6z M199.9,40.7l0.3-0.1V27.8h2.5 v17.8l-1,0.3l-12.3-13l-0.3,0.1v12.7h-2.5V27.9l1-0.3L199.9,40.7z M220.1,41.5h-8.2l-1.9,4.3l-2.6-0.4l8.3-17.8h0.5l8.4,17.8 l-2.6,0.4L220.1,41.5z M212.9,39.2h6.1l-3-6.6h-0.1L212.9,39.2z M243.5,45v0.4l-2.4,0.5l-6.3-7.2h-2.9v7h-2.5V27.8h6.5 c3.7,0,6.1,2.2,6.1,5.3c0,2.7-1.6,4.7-4.4,5.2L243.5,45z M235.8,30.1h-3.8v6.3h3.8c2.3,0,3.7-1.1,3.7-3.3 C239.5,31.1,237.9,30.1,235.8,30.1z M248.5,41.7c1.5,1.2,3.2,1.9,5.6,1.9c3.1,0,4.2-1.3,4.2-2.7c0-1.6-1.5-2.3-4.5-3.6 c-4.1-1.8-5.5-2.9-5.5-5.2s2.1-4.7,6.1-4.7c2.7,0,4.9,0.9,6,1.9l-0.9,2.1c-1.5-1.1-3.2-1.6-5.1-1.6c-2.3,0-3.7,1-3.7,2.2 c0,1.3,1.1,1.9,4.7,3.4c4.1,1.6,5.4,3.3,5.4,5.7c0,3-2.6,4.9-6.9,4.9c-2.9,0-5.5-1.1-6.5-2.1L248.5,41.7z M122.8,4.6h-8.1v3h7.1v3.8 h-7.1v3.2h8.4v4H110V0.6h12.8L122.8,4.6L122.8,4.6z M141.2,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L141.2,10.9z M151.7,18.7V0.6h6.4c5.4,0,9.5,3.7,9.5,9.1c0,5.8-4,9.1-9.5,9.1C158.1,18.7,151.7,18.7,151.7,18.7z M158.4,14.7 c2.6,0,4.4-1.8,4.4-5.1c0-3.1-2.5-4.9-4.5-4.9h-2.1v10.1C156.2,14.7,158.4,14.7,158.4,14.7z M178.9,12.5H177v6.2h-4.7V0.6h6.7 c4.1,0,7,2.4,7,6.3C186,9.3,184.3,12.5,178.9,12.5z M178.5,4.4H177v4.5h1.6c1.5,0,2.5-0.7,2.5-2.1C181.1,5.5,180,4.4,178.5,4.4z M199.3,19.1c-5.7,0-9.7-4.1-9.7-9.3c0-5.8,4.7-9.5,9.7-9.5c4.9,0,9.7,3.7,9.7,9.5C208.9,14.9,205.1,19.1,199.3,19.1z M199.2,4.4 c-2.5,0-4.9,1.9-4.9,5.3c0,2.7,1.6,5.3,4.9,5.3c2.7,0,4.9-2,4.9-5.3C204.1,6.5,201.9,4.4,199.2,4.4z M218.6,18.7h-4.7V0.6h4.7V18.7z M237.3,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L237.3,10.9z M257,4.6v14.1h-4.7V4.6h-5.5v-4h15.6v4H257L257,4.6z M267.1,13.2c1.6,1,3.7,1.9,5.8,1.9c1.6,0,2.4-0.7,2.4-1.5c0-1.1-1.2-1.5-3.5-2.6c-3.7-1.7-5.2-3-5.2-5.7s2.2-5.2,6.7-5.2 c2.6,0,4.8,0.6,6.4,1.7l-1.2,3.8c-1.8-1-3.6-1.6-5.3-1.6c-1.4,0-2,0.5-2,1.3s0.7,1.2,3.6,2.5c3.9,1.8,5.3,3.5,5.3,5.9 c0,3.4-3.1,5.2-7.4,5.2c-3.1,0-5.8-1.1-6.9-2.1L267.1,13.2z"></path> </svg> </div> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation"> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> <div class="collapse navbar-collapse offset" id="navbarSupportedContent"> <ul class="nav navbar-nav menu_nav justify-content-end"> <li class="nav-item"> <a class="nav-link" href="https://endpts.com" target="_blank" title="Endpoints News">Endpoints News</a> </li> <li class="reg-button" data-block-name="register">watch now</li> </ul> </div> </div> </nav> </div> </header> <section id="hero-section"> <div class="container"> <div class="row d-flex no-gutters date-time"> <div class="on-demand">WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND</div> </div> <div class="hero-content"> <h1>The checkpoint debate is about to get real</h1> <div class="abstract"> <p>Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.</p> </div>  </div> </div> <div class="fixed-bottom cta-fixed"> <div class="container"> <div class="row d-flex"> <div class="col-md-3 align-self-center social order-3 order-md-1">SHARE ON <a href="https://www.linkedin.com/shareArticle?mini=true&source=https%3A%2F%2Fwebinars.endpts.com%2F&title=Endpoints+Webinars%3A+The+checkpoint+debate+is+about+to+get+real&url=https%3A%2F%2Fwebinars.endpts.com%2Fthe-checkpoint-debate-is-about-to-get-real" target="_blank" rel="noopener nofollow"><img src="/assets/images/social/social-linkedin.svg"></a> <a href="https://twitter.com/intent/tweet?text=Endpoints+Webinars%3A+The+checkpoint+debate+is+about+to+get+real+https%3A%2F%2Fwebinars.endpts.com%2Fthe-checkpoint-debate-is-about-to-get-real" target="_blank" rel="noopener nofollow"><img src="/assets/images/social/social-twitter.svg"></a> </div> <div class="col-md-5 order-1"> </div> <div class="col-md-4 align-self-center order-2"> <div class="reg-button" data-block-name="register">watch now</div> </div> </div> </div> </div> </section><section class="pt-5 register-section" id="register"> <div class="container register-states pt-4"> <div class="section-title mb-0">Watch the webinar on demand</div> <div class="col-md-4 m-auto"> <a class="reg-button" href="https://vimeo.com/670920292/8c985ba1c8" target="_blank">watch now</a> </div> </div> </section> <section class="speakers-section"> <div class="container"> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <div> <img class="card-img rounded-circle" src="/assets/images/the-checkpoint-debate-is-about-to-get-real/panelists/JuanJaen.jpg" alt="Juan Jaen"> </div> </div> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Juan Jaen</h3> <h5>President, Arcus Biosciences</h5> <p>Dr. Jaen, PhD, has been engaged in all aspects of drug discovery and development for more than 30 years, and in 2015 he co-founded Arcus. Before starting Arcus, Dr. Jaen was co-founder and President of Flexus Biosciences. He was Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx for 7 years, where he led the discovery and progression into the clinic of 8 novel immunology drug candidates. Dr. Jaen has also held various positions at Amgen, Tularik, and Parke-Davis/Warner-Lambert. He is an inventor on 50 patents and has helped the advancement of over 20 novel molecules into clinical development across a range of indications.</p> </div> </div> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <div> <img class="card-img rounded-circle" src="/assets/images/the-checkpoint-debate-is-about-to-get-real/panelists/StephenODay.jpg" alt="Steven O'Day"> </div> </div> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Steven O'Day</h3> <h5>Chief Medical Officer, Agenus</h5> <p>Dr. Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Steven played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.</p> </div> </div> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <div> <img class="card-img rounded-circle" src="/assets/images/the-checkpoint-debate-is-about-to-get-real/panelists/LeenaGandhi.jpeg" alt="Leena Gandhi"> </div> </div> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Leena Gandhi</h3> <h5>Director, Center for Cancer Therapeutic Innovation, Dana-Farber Cancer Institute</h5> <p>Dr. Leena Gandhi received her PhD from the University of California, Berkeley and her MD from New York University prior to completing postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. She was a thoracic oncologist working in Early Drug Development at DFCI until 2016 when she moved to NYU Perlmutter Cancer Center to serve as the Director of Thoracic Medical Oncology. She has focused her research on novel drug development and biomarkers for selection in lung cancer with a particular focus on immuno-oncology. She led pivotal studies demonstrating the utility of PDL1 as a biomarker for efficacy of anti-PD1 agents in lung cancer and studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. She served as Vice President of Immuno-Oncology Development at Eli Lilly leading the development of novel immuno-oncology agents across cancer types and was recruited back to DFCI in 2020 as the Director of the Center for Cancer Therapeutic Innovation, an integrated clinical/translational research center that brings together specialized cancer expertise to develop and conduct innovative early phase clinical trials spanning multiple malignancies. </p> </div> </div> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <div> <img class="card-img rounded-circle" src="/assets/images/the-checkpoint-debate-is-about-to-get-real/panelists/JonathanCheng.jpg" alt="Jonathan Cheng"> </div> </div> <div class="col-lg-9 col-sm-8 speaker-info"> <h3>Jonathan Cheng</h3> <h5>Senior Vice President and Head of Oncology Development, Global Drug Development, Bristol Myers Squibb</h5> <p>Jonathan Cheng, MD, is Senior Vice President and Head of Oncology Development and a member of Samit Hirawat’s Global Drug Development Leadership Team.</p> <p>Jon’s background as a medical oncologist and cancer researcher has provided him extensive drug development experience in both academia and industry for over 20 years. Jon joined BMS in September 2020 as the therapeutic area head of oncology clinical development, managing the portfolio of solid tumor clinical trials. Prior to joining BMS, Jon held roles of increasing responsibility over 11 years at Merck where he was most recently Vice President Oncology Therapeutic Lead. And prior to that he was in academia for 11 years as an Associate Professor at Fox Chase Cancer Center where he led as Principal Investigator (PI) a tumor microenvironment drug development team, and where he continues to see patients weekly as an Adjunct Professor. </p> </div> </div> <div class="row speaker-row align-items-top"> <div class="col-lg-3 col-sm-4 mb-lg-0 mb-4"> <div> <img class="card-img rounded-circle" src="/assets/images/the-checkpoint-debate-is-about-to-get-real/panelists/KyleBlankenship.jpg" alt="Kyle Blankenship"> </div> </div> <div class="col-lg-9 col-sm-8 speaker-info"> <h6>moderator</h6> <h3>KYLE BLANKENSHIP</h3> <h5>MANAGING EDITOR, ENDPOINTS NEWS</h5> <p>A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor roles at two daily newspapers in Texas. In addition to a bachelor’s degree from Texas A&M University, Kyle holds a master’s degree in journalism from the University of North Texas in Denton. At Endpoints, Kyle leads the company’s manufacturing coverage as well as running point on virtual events, editing and content strategy. An avid cook and history nerd, you can find Kyle hovering over the stove—spatula in one hand and a World War II tome in the other.</p> </div> </div> </div> </section> <div class="modal" role="dialog" id="registration_success" aria-hidden="true"> <div class="modal-dialog modal-dialog-centered" role="document"> <div class="modal-content"> <div class="modal-header align-items-center"> <svg version="1.1" width="280px" class="d-inline-block align-top ew-logo" alt="Endpoints Webinars" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewbox="0 0 280 46" style="enable-background:new 0 0 280 46;" xml:space="preserve"> <path class="ew-logo-primary" d="M84.3,0.2l-7.7,24.1h-0.5l-8-24.1h-7.8l-7.3,24.1h-0.5L44.3,0.2h-4h-8.8H0V46h39l-3.9-10.2h-24v-8.1h20.6 L28.1,18h-17v-7.6h24.3L48.7,46h7.7l8-25.6h0.4L72.2,46h7.7L97.1,0.2H84.3z"/> <path class="ew-logo-secondary" d="M122.2,33.3l-4.5,12.5h-1l-7-17.7l2.5-0.5l4.9,12.8h0.2l4.5-12.8h0.6l4.7,12.8h0.2l4.8-12.8l2.5,0.5l-7,17.7h-1 L122.2,33.3C122.4,33.3,122.2,33.3,122.2,33.3z M151.2,30.1H142v5.3h8.1v2.3H142v5.7h9.5v2.3h-12.1V27.8h11.7L151.2,30.1L151.2,30.1 z M166.8,36.5c2.2,0.4,3.7,2.1,3.7,4.2c0,3.1-2.4,4.9-6.3,4.9h-6.4V27.8h5.9c4.2,0,5.8,2.4,5.8,4.7c0,1.6-0.8,3.1-2.6,3.8V36.5 L166.8,36.5z M163.7,30.1h-3.5v5.3h3.6c1.9,0,2.9-0.9,2.9-2.7C166.7,30.7,165.3,30.1,163.7,30.1z M160.2,37.7v5.7h4.2 c1.9,0,3.4-0.9,3.4-2.8s-1.6-2.9-3.6-2.9L160.2,37.7L160.2,37.7z M179.1,45.6h-2.5V27.8h2.5V45.6z M199.9,40.7l0.3-0.1V27.8h2.5 v17.8l-1,0.3l-12.3-13l-0.3,0.1v12.7h-2.5V27.9l1-0.3L199.9,40.7z M220.1,41.5h-8.2l-1.9,4.3l-2.6-0.4l8.3-17.8h0.5l8.4,17.8 l-2.6,0.4L220.1,41.5z M212.9,39.2h6.1l-3-6.6h-0.1L212.9,39.2z M243.5,45v0.4l-2.4,0.5l-6.3-7.2h-2.9v7h-2.5V27.8h6.5 c3.7,0,6.1,2.2,6.1,5.3c0,2.7-1.6,4.7-4.4,5.2L243.5,45z M235.8,30.1h-3.8v6.3h3.8c2.3,0,3.7-1.1,3.7-3.3 C239.5,31.1,237.9,30.1,235.8,30.1z M248.5,41.7c1.5,1.2,3.2,1.9,5.6,1.9c3.1,0,4.2-1.3,4.2-2.7c0-1.6-1.5-2.3-4.5-3.6 c-4.1-1.8-5.5-2.9-5.5-5.2s2.1-4.7,6.1-4.7c2.7,0,4.9,0.9,6,1.9l-0.9,2.1c-1.5-1.1-3.2-1.6-5.1-1.6c-2.3,0-3.7,1-3.7,2.2 c0,1.3,1.1,1.9,4.7,3.4c4.1,1.6,5.4,3.3,5.4,5.7c0,3-2.6,4.9-6.9,4.9c-2.9,0-5.5-1.1-6.5-2.1L248.5,41.7z M122.8,4.6h-8.1v3h7.1v3.8 h-7.1v3.2h8.4v4H110V0.6h12.8L122.8,4.6L122.8,4.6z M141.2,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L141.2,10.9z M151.7,18.7V0.6h6.4c5.4,0,9.5,3.7,9.5,9.1c0,5.8-4,9.1-9.5,9.1C158.1,18.7,151.7,18.7,151.7,18.7z M158.4,14.7 c2.6,0,4.4-1.8,4.4-5.1c0-3.1-2.5-4.9-4.5-4.9h-2.1v10.1C156.2,14.7,158.4,14.7,158.4,14.7z M178.9,12.5H177v6.2h-4.7V0.6h6.7 c4.1,0,7,2.4,7,6.3C186,9.3,184.3,12.5,178.9,12.5z M178.5,4.4H177v4.5h1.6c1.5,0,2.5-0.7,2.5-2.1C181.1,5.5,180,4.4,178.5,4.4z M199.3,19.1c-5.7,0-9.7-4.1-9.7-9.3c0-5.8,4.7-9.5,9.7-9.5c4.9,0,9.7,3.7,9.7,9.5C208.9,14.9,205.1,19.1,199.3,19.1z M199.2,4.4 c-2.5,0-4.9,1.9-4.9,5.3c0,2.7,1.6,5.3,4.9,5.3c2.7,0,4.9-2,4.9-5.3C204.1,6.5,201.9,4.4,199.2,4.4z M218.6,18.7h-4.7V0.6h4.7V18.7z M237.3,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L237.3,10.9z M257,4.6v14.1h-4.7V4.6h-5.5v-4h15.6v4H257L257,4.6z M267.1,13.2c1.6,1,3.7,1.9,5.8,1.9c1.6,0,2.4-0.7,2.4-1.5c0-1.1-1.2-1.5-3.5-2.6c-3.7-1.7-5.2-3-5.2-5.7s2.2-5.2,6.7-5.2 c2.6,0,4.8,0.6,6.4,1.7l-1.2,3.8c-1.8-1-3.6-1.6-5.3-1.6c-1.4,0-2,0.5-2,1.3s0.7,1.2,3.6,2.5c3.9,1.8,5.3,3.5,5.3,5.9 c0,3.4-3.1,5.2-7.4,5.2c-3.1,0-5.8-1.1-6.9-2.1L267.1,13.2z"/> </svg> <button class="ui_form_close" data-dismiss="modal">close</button> </div> <div class="modal-body"> <div class="row"> <div class="col-12 modal-container"> <h1>Your seat is reserved!</h1> <h2>The checkpoint debate is about to get real</h2> <div class="time"> 2:00 pm - 3:00 pm EST </div> <div class="time local-time">LOCAL TIME</div> <p>A confirmation email with information on how to join the webinar has been sent to you.</p> <p>Before joining, be sure to check <a href="https://support.zoom.us/hc/en-us/articles/201362023-System-requirements-for-Windows-macOS-and-Linux" target="_blank">system requirements</a> to avoid any connection issues. </p> </div> </div> </div> </div> </div> </div> <div class="modal" role="dialog" id="registration_declined" aria-hidden="true"> <div class="modal-dialog modal-dialog-centered" role="document"> <div class="modal-content"> <div class="modal-header align-items-center"> <svg version="1.1" width="280px" class="d-inline-block align-top ew-logo" alt="Endpoints Webinars" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewbox="0 0 280 46" style="enable-background:new 0 0 280 46;" xml:space="preserve"> <path class="ew-logo-primary" d="M84.3,0.2l-7.7,24.1h-0.5l-8-24.1h-7.8l-7.3,24.1h-0.5L44.3,0.2h-4h-8.8H0V46h39l-3.9-10.2h-24v-8.1h20.6 L28.1,18h-17v-7.6h24.3L48.7,46h7.7l8-25.6h0.4L72.2,46h7.7L97.1,0.2H84.3z"/> <path class="ew-logo-secondary" d="M122.2,33.3l-4.5,12.5h-1l-7-17.7l2.5-0.5l4.9,12.8h0.2l4.5-12.8h0.6l4.7,12.8h0.2l4.8-12.8l2.5,0.5l-7,17.7h-1 L122.2,33.3C122.4,33.3,122.2,33.3,122.2,33.3z M151.2,30.1H142v5.3h8.1v2.3H142v5.7h9.5v2.3h-12.1V27.8h11.7L151.2,30.1L151.2,30.1 z M166.8,36.5c2.2,0.4,3.7,2.1,3.7,4.2c0,3.1-2.4,4.9-6.3,4.9h-6.4V27.8h5.9c4.2,0,5.8,2.4,5.8,4.7c0,1.6-0.8,3.1-2.6,3.8V36.5 L166.8,36.5z M163.7,30.1h-3.5v5.3h3.6c1.9,0,2.9-0.9,2.9-2.7C166.7,30.7,165.3,30.1,163.7,30.1z M160.2,37.7v5.7h4.2 c1.9,0,3.4-0.9,3.4-2.8s-1.6-2.9-3.6-2.9L160.2,37.7L160.2,37.7z M179.1,45.6h-2.5V27.8h2.5V45.6z M199.9,40.7l0.3-0.1V27.8h2.5 v17.8l-1,0.3l-12.3-13l-0.3,0.1v12.7h-2.5V27.9l1-0.3L199.9,40.7z M220.1,41.5h-8.2l-1.9,4.3l-2.6-0.4l8.3-17.8h0.5l8.4,17.8 l-2.6,0.4L220.1,41.5z M212.9,39.2h6.1l-3-6.6h-0.1L212.9,39.2z M243.5,45v0.4l-2.4,0.5l-6.3-7.2h-2.9v7h-2.5V27.8h6.5 c3.7,0,6.1,2.2,6.1,5.3c0,2.7-1.6,4.7-4.4,5.2L243.5,45z M235.8,30.1h-3.8v6.3h3.8c2.3,0,3.7-1.1,3.7-3.3 C239.5,31.1,237.9,30.1,235.8,30.1z M248.5,41.7c1.5,1.2,3.2,1.9,5.6,1.9c3.1,0,4.2-1.3,4.2-2.7c0-1.6-1.5-2.3-4.5-3.6 c-4.1-1.8-5.5-2.9-5.5-5.2s2.1-4.7,6.1-4.7c2.7,0,4.9,0.9,6,1.9l-0.9,2.1c-1.5-1.1-3.2-1.6-5.1-1.6c-2.3,0-3.7,1-3.7,2.2 c0,1.3,1.1,1.9,4.7,3.4c4.1,1.6,5.4,3.3,5.4,5.7c0,3-2.6,4.9-6.9,4.9c-2.9,0-5.5-1.1-6.5-2.1L248.5,41.7z M122.8,4.6h-8.1v3h7.1v3.8 h-7.1v3.2h8.4v4H110V0.6h12.8L122.8,4.6L122.8,4.6z M141.2,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L141.2,10.9z M151.7,18.7V0.6h6.4c5.4,0,9.5,3.7,9.5,9.1c0,5.8-4,9.1-9.5,9.1C158.1,18.7,151.7,18.7,151.7,18.7z M158.4,14.7 c2.6,0,4.4-1.8,4.4-5.1c0-3.1-2.5-4.9-4.5-4.9h-2.1v10.1C156.2,14.7,158.4,14.7,158.4,14.7z M178.9,12.5H177v6.2h-4.7V0.6h6.7 c4.1,0,7,2.4,7,6.3C186,9.3,184.3,12.5,178.9,12.5z M178.5,4.4H177v4.5h1.6c1.5,0,2.5-0.7,2.5-2.1C181.1,5.5,180,4.4,178.5,4.4z M199.3,19.1c-5.7,0-9.7-4.1-9.7-9.3c0-5.8,4.7-9.5,9.7-9.5c4.9,0,9.7,3.7,9.7,9.5C208.9,14.9,205.1,19.1,199.3,19.1z M199.2,4.4 c-2.5,0-4.9,1.9-4.9,5.3c0,2.7,1.6,5.3,4.9,5.3c2.7,0,4.9-2,4.9-5.3C204.1,6.5,201.9,4.4,199.2,4.4z M218.6,18.7h-4.7V0.6h4.7V18.7z M237.3,10.9h0.2V0.6h4.7v18.1h-3l-9.7-10.3h-0.2v10.3h-4.7V0.6h3L237.3,10.9z M257,4.6v14.1h-4.7V4.6h-5.5v-4h15.6v4H257L257,4.6z M267.1,13.2c1.6,1,3.7,1.9,5.8,1.9c1.6,0,2.4-0.7,2.4-1.5c0-1.1-1.2-1.5-3.5-2.6c-3.7-1.7-5.2-3-5.2-5.7s2.2-5.2,6.7-5.2 c2.6,0,4.8,0.6,6.4,1.7l-1.2,3.8c-1.8-1-3.6-1.6-5.3-1.6c-1.4,0-2,0.5-2,1.3s0.7,1.2,3.6,2.5c3.9,1.8,5.3,3.5,5.3,5.9 c0,3.4-3.1,5.2-7.4,5.2c-3.1,0-5.8-1.1-6.9-2.1L267.1,13.2z"/> </svg> <button class="ui_form_close" data-dismiss="modal">close</button> </div> <div class="modal-body"> <div class="row"> <div class="col-12 modal-container"> <h1>Registration declined</h1> <h2>The checkpoint debate is about to get real</h2> <p class="mt-3">The webinar sponsor has requested specific attendance parameters for this webinar.</p> <p>We apologize for any inconvenience this may cause and we hope you will join us for future webinars.</p> </div> </div> </div> </div> </div> </div> <script src="https://webinars.endpts.com/assets/js/jquery-3.4.1.min.js" type="text/javascript"></script> <script src="https://webinars.endpts.com/assets/js/bootstrap.bundle.min.js" type="text/javascript"></script> <script src="https://webinars.endpts.com/assets/js/main.js?v=1.0.17" type="text/javascript"></script><script type='text/javascript'>/* <![CDATA[ */var webinar = {"id":86413161833,"title":"The checkpoint debate is about to get real","start":1643310000,"end":1643313600,"fields":{"email":{"name":"email","required":true},"first_name":{"name":"first_name","required":true},"last_name":{"name":"last_name","required":true},"country":{"name":"country","required":true,"answers":{"AF":"Afghanistan","AX":"\u00c5land Islands","AL":"Albania","DZ":"Algeria","AS":"American Samoa","AD":"Andorra","AO":"Angola","AI":"Anguilla","AQ":"Antarctica","AG":"Antigua and Barbuda","AR":"Argentina","AM":"Armenia","AW":"Aruba","AU":"Australia","AT":"Austria","AZ":"Azerbaijan","BS":"Bahamas","BH":"Bahrain","BD":"Bangladesh","BB":"Barbados","BY":"Belarus","BE":"Belgium","BZ":"Belize","BJ":"Benin","BM":"Bermuda","BT":"Bhutan","BO":"Bolivia","BQ":"Bonaire, Sint Eustatius and Saba","BA":"Bosnia and Herzegovina","BW":"Botswana","BV":"Bouvet Island","BR":"Brazil","IO":"British Indian Ocean Territory","BN":"Brunei Darussalam","BG":"Bulgaria","BF":"Burkina Faso","BI":"Burundi","CV":"Cabo Verde","KH":"Cambodia","CM":"Cameroon","CA":"Canada","KY":"Cayman Islands","CF":"Central African Republic","TD":"Chad","CL":"Chile","CN":"China","CX":"Christmas Island","CC":"Cocos (Keeling) Islands","CO":"Colombia","KM":"Comoros","CG":"Congo","CD":"Congo","CK":"Cook Islands","CR":"Costa Rica","CI":"C\u00f4te d'Ivoire","HR":"Croatia","CW":"Cura\u00e7ao","CY":"Cyprus","CZ":"Czechia","DK":"Denmark","DJ":"Djibouti","DM":"Dominica","DO":"Dominican Republic","EC":"Ecuador","EG":"Egypt","SV":"El Salvador","GQ":"Equatorial Guinea","ER":"Eritrea","EE":"Estonia","SZ":"Eswatini","ET":"Ethiopia","FK":"Falkland Islands (Malvinas)","FO":"Faroe Islands","FJ":"Fiji","FI":"Finland","FR":"France","GF":"French Guiana","PF":"French Polynesia","TF":"French Southern Territories","GA":"Gabon","GM":"Gambia","GE":"Georgia","DE":"Germany","GH":"Ghana","GI":"Gibraltar","GR":"Greece","GL":"Greenland","GD":"Grenada","GP":"Guadeloupe","GU":"Guam","GT":"Guatemala","GG":"Guernsey","GN":"Guinea","GW":"Guinea-Bissau","GY":"Guyana","HT":"Haiti","HM":"Heard Island and McDonald Islands","VA":"Holy See","HN":"Honduras","HK":"Hong Kong SAR","HU":"Hungary","IS":"Iceland","IN":"India","ID":"Indonesia","IQ":"Iraq","IE":"Ireland","IM":"Isle of Man","IL":"Israel","IT":"Italy","JM":"Jamaica","JP":"Japan","JE":"Jersey","JO":"Jordan","KZ":"Kazakhstan","KE":"Kenya","KI":"Kiribati","KR":"Korea","KW":"Kuwait","KG":"Kyrgyzstan","LA":"Lao People's Democratic Republic","LV":"Latvia","LB":"Lebanon","LS":"Lesotho","LR":"Liberia","LY":"Libya","LI":"Liechtenstein","LT":"Lithuania","LU":"Luxembourg","MO":"Macau SAR","MG":"Madagascar","MW":"Malawi","MY":"Malaysia","MV":"Maldives","ML":"Mali","MT":"Malta","MH":"Marshall Islands","MQ":"Martinique","MR":"Mauritania","MU":"Mauritius","YT":"Mayotte","MX":"Mexico","FM":"Micronesia","MD":"Moldova","MC":"Monaco","MN":"Mongolia","ME":"Montenegro","MS":"Montserrat","MA":"Morocco","MZ":"Mozambique","MM":"Myanmar","NA":"Namibia","NR":"Nauru","NP":"Nepal","NL":"Netherlands","NC":"New Caledonia","NZ":"New Zealand","NI":"Nicaragua","NE":"Niger","NG":"Nigeria","NU":"Niue","NF":"Norfolk Island","MP":"Northern Mariana Islands","MK":"North Macedonia","NO":"Norway","OM":"Oman","PK":"Pakistan","PW":"Palau","PS":"Palestine","PA":"Panama","PG":"Papua New Guinea","PY":"Paraguay","PE":"Peru","PH":"Philippines","PN":"Pitcairn","PL":"Poland","PT":"Portugal","PR":"Puerto Rico","QA":"Qatar","RE":"R\u00e9union","RO":"Romania","RU":"Russian Federation","RW":"Rwanda","BL":"Saint Barth\u00e9lemy","SH":"Saint Helena, Ascension and Tristan da Cunha","KN":"Saint Kitts and Nevis","LC":"Saint Lucia","MF":"Saint Martin (French part)","PM":"Saint Pierre and Miquelon","VC":"Saint Vincent and the Grenadines","WS":"Samoa","SM":"San Marino","ST":"Sao Tome and Principe","SA":"Saudi Arabia","SN":"Senegal","RS":"Serbia","SC":"Seychelles","SL":"Sierra Leone","SG":"Singapore","SX":"Sint Maarten (Dutch part)","SK":"Slovakia","SI":"Slovenia","SB":"Solomon Islands","SO":"Somalia","ZA":"South Africa","GS":"South Georgia and the South Sandwich Islands","SS":"South Sudan","ES":"Spain","LK":"Sri Lanka","SR":"Suriname","SJ":"Svalbard and Jan Mayen","SE":"Sweden","CH":"Switzerland","TW":"Taiwan","TJ":"Tajikistan","TZ":"Tanzania","TH":"Thailand","TL":"Timor-Leste","TG":"Togo","TK":"Tokelau","TO":"Tonga","TT":"Trinidad and Tobago","TN":"Tunisia","TR":"Turkey","TM":"Turkmenistan","TC":"Turks and Caicos Islands","TV":"Tuvalu","UG":"Uganda","UA":"Ukraine","AE":"United Arab Emirates","GB":"United Kingdom","UM":"United States Minor Outlying Islands","US":"United States of America","UY":"Uruguay","UZ":"Uzbekistan","VU":"Vanuatu","VE":"Venezuela","VN":"Viet Nam","VG":"Virgin Islands (British)","VI":"Virgin Islands (U.S.)","WF":"Wallis and Futuna","EH":"Western Sahara","YE":"Yemen","ZM":"Zambia","ZW":"Zimbabwe","Other":"Other"}},"org":{"name":"org","required":true},"job_title":{"name":"job_title","required":true}},"vimeo_link":"https:\/\/vimeo.com\/670920292\/8c985ba1c8"};/* ]]> */</script><script>!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '174990157837477'); fbq('track', 'PageView'); _linkedin_partner_id = "2273916"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); (function(w,d,t,r,u){var f,n,i;w[u]=w[u]||[],f=function(){var o={ti:"56366962"};o.q=w[u],w[u]=new UET(o),w[u].push("pageLoad")},n=d.createElement(t),n.src=r,n.async=1,n.onload=n.onreadystatechange=function(){var s=this.readyState;s&&s!=="loaded"&&s!=="complete"||(f(),n.onload=n.onreadystatechange=null)},i=d.getElementsByTagName(t)[0],i.parentNode.insertBefore(n,i)})(window,document,"script","//bat.bing.com/bat.js","uetq"); </script> </body> </html>

CINXE.COM

The checkpoint debate is about to get real - Endpoints Webinars